Cannabidiol Alleviates Imiquimod-Induced Psoriasis by Inhibiting JAK2-STAT3 in a Mouse Model

Area of Science:

• Dermatology
• Pharmacology
• Immunology

Background:

• Psoriasis is a chronic inflammatory skin disease affecting 1-3% of the global population.
• Cannabidiol (CBD), a non-psychoactive compound from Cannabis sativa, shows potential therapeutic benefits.
• The precise mechanisms by which CBD alleviates psoriasis symptoms are not fully understood.

Purpose of the Study:

• To investigate the therapeutic effects of CBD on imiquimod (IMQ)-induced psoriasis in a mouse model.
• To elucidate the molecular mechanisms underlying CBD's anti-psoriatic activity, focusing on inflammatory markers and signaling pathways.

Main Methods:

• Psoriasis was induced in mice using IMQ, followed by topical application of clobetasol or varying concentrations of CBD.
• Psoriasis severity was evaluated using the Psoriasis Area and Severity Index (PASI) and histopathological analysis.
• Gene expression of key inflammatory markers (e.g., IL-1β, IL-6, TNF-α) and protein levels of the JAK2-STAT3 signaling pathway components were analyzed.

Main Results:

• CBD treatment significantly reduced PASI scores, epidermal thickness, keratosis, hyperproliferation, and overall inflammation in IMQ-induced psoriasis.
• CBD application led to the downregulation of inflammatory gene expression, including IL-1β, IL-6, IL-12b, IL-17a, IL-22, and TNF.
• CBD inhibited the IL-23 receptor-mediated JAK2-STAT3 signaling pathway, indicating a key mechanism of action.

Conclusions:

• CBD demonstrates significant efficacy in alleviating psoriasis-like symptoms in a mouse model.
• CBD's therapeutic effects are mediated by the inhibition of the JAK2-STAT3 signaling pathway and subsequent reduction in inflammatory cytokine production.
• CBD represents a promising therapeutic candidate for managing psoriasis, warranting further clinical investigation.